SEC Comment Letter 0000000000-23-006169 to G1 Therapeutics, Inc. (GTHX) (CIK 0001560241)

G1 Therapeutics, Inc. (GTHX) (CIK 0001560241)
Date: June 8, 2023 · CIK: 0001560241 · Accession: 0000000000-23-006169

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-38096

Date

June 8, 2023

Author

John Umstead

Form

UPLOAD

Company

G1 Therapeutics, Inc. (GTHX) (CIK 0001560241)

Letter

United States securities and exchange commission logo June 8, 2023 John Umstead Chief Financial Officer G1 Therapeutics, Inc. 700 Park Offices Drive, Suite 200 Research Triangle Park, North Carolina 27709 Re:G1 Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed March 1, 2023 File No. 001-38096 Dear John Umstead: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

United States securities and exchange commission logo
June 8, 2023
John Umstead
Chief Financial Officer
G1 Therapeutics, Inc.
700 Park Offices Drive, Suite 200
Research Triangle Park, North Carolina 27709
Re:G1 Therapeutics, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2022
Filed March 1, 2023
File No. 001-38096
Dear John Umstead:
            We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io